Hepatic Steatosis Pathophysiology and Clinical Significance

Core Metabolic Mechanisms

The American Association for the Study of Liver Diseases suggests that enhanced influx of free fatty acids from adipose tissue and chylomicrons from the intestinal mucosa directly to the liver contributes to hepatic triglycerides in most patients with metabolic dysfunction 1
Alcohol oxidation increases NADH synthesis, which drives triglyceride and fatty acid production while simultaneously suppressing mitochondrial β-oxidation, according to the American Association for the Study of Liver Diseases 1
Ethanol-mediated suppression of AMPK activation results in increased lipid biosynthesis, as reported by the American Association for the Study of Liver Diseases 1
Activation of SREBP1c further amplifies lipogenesis while suppression of PPARα decreases lipolysis, as noted by the American Association for the Study of Liver Diseases 1
Acetaldehyde-induced mitochondrial and microtubule damage decreases NADH oxidation and causes VLDL accumulation, according to the American Association for the Study of Liver Diseases 1

The European Association for the Study of the Liver states that macrovescicular steatosis involves large lipid droplets occupying the entire cytoplasm and is characteristically associated with alcohol, obesity, and diabetes 2
The European Association for the Study of the Liver notes that microvescicular steatosis consists of tiny lipid droplets (<1 mm) creating a foamy cytoplasmic appearance, associated with drug toxicity, acute fatty liver of pregnancy, and Reye syndrome 2
Macrovescicular steatosis carries greater clinical significance for disease progression, while microvescicular patterns typically do not preclude organ function, as reported by the European Association for the Study of the Liver 2

The American Association for the Study of Liver Diseases defines simple steatosis (NAFL) as hepatic steatosis without hepatocellular injury or ballooning, representing 70-75% of NAFLD/MASLD cases 5
Most patients with simple steatosis remain asymptomatic and exhibit very slow or absent histological progression, according to the American Association for the Study of Liver Diseases 5
Steatohepatitis (NASH/MASH) occurs in 25-30% of cases and represents a critical pathophysiologic transition, characterized by hepatic steatosis plus inflammation with hepatocyte injury (ballooning), with or without fibrosis, as noted by the American Association for the Study of Liver Diseases 5
Patients with steatohepatitis can exhibit histological progression to cirrhotic-stage disease, according to the American Association for the Study of Liver Diseases 5

The American Association for the Study of Liver Diseases states that NAFLD/MASLD is intrinsically linked to metabolic risk factors including obesity, type 2 diabetes, and dyslipidemia 5
The American Diabetes Association notes that the prevalence of NAFLD/MASLD reaches 70% in obesity and 90% in diabetes 3

The American Gastroenterological Association notes that the majority (60-80%) of patients with chronic hepatic steatosis remain completely asymptomatic because simple steatosis occurs without cellular injury or inflammation 4
The American Gastroenterological Association suggests that early detection is challenging due to the silent nature of the disease and underscores the importance of screening high-risk populations despite normal liver biochemistries 6